[Countermeasure for infections with granulocytopenia].
Sotoyama
K
K
D000380:Agranulocytosis / Q000150:complications / Q000188:drug therapy*; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy / Q000209:etiology; D002511:Cephalosporins / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008825:Miconazole / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D018805:Sepsis / Q000188:drug therapy* / Q000209:etiology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D011994:Recombinant Proteins; D008825:Miconazole; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015725:Fluconazole